# Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners

> **NCT03965741** · — · COMPLETED · sponsor: **Bayer** · enrollment: 97765 (actual)

## Conditions studied

- Venous Thromboembolism (VTE)

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Apixaban(Eliquis)
- **DRUG:** Pradaxa (Dabigatran etexilate)

## Key facts

- **NCT ID:** NCT03965741
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-30
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 97765 (ACTUAL)
- **Last updated:** 2021-11-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03965741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03965741, "Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03965741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*